AstraZeneca's Farxiga Approved For Treating Pediatric Type-2 Diabetes in U.S.
By Ben Glickman
AstraZeneca's diabetes drug Farxiga on Wednesday was approved by U.S. regulators for the treatment of type-2 diabetes in children 10 and older.
Farxiga, which goes by generic name dapagliflozin, was already approved by the U.S. Food and Drug Administration in adults with type-2 diabetes, when used as an adjunct to diet and exercise to improve glycemic control.
The pharmaceutical company said the approval was based on results in a pediatric Phase 3 trial. AstraZeneca said the trial showed a statistically significant improvement in glycemia for children and adolescents with the disease.
Farxiga is already approved for treating pediatric type-2 diabetes patients in 56 countries, including the European Union. The medicine is sold under the brand name Forxiga in the EU.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
June 12, 2024 18:16 ET (22:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now